Tag
A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.
Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.
A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.
The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant
The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant
High tibial osteotomy (HTO) slows cartilage loss and improves pain and function in bowlegged patients with medial knee osteoarthritis compared to nonsurgical management, according to a new randomized trial.
The FDA has granted Fast Track status to rezpegaldesleukin (REZPEG), a novel biologic targeting regulatory T cells, for severe-to-very severe alopecia areata in patients aged ≥12 years. Phase 2b trial results are anticipated in December 202
DM199 has demonstrated safety and efficacy in reducing blood pressure among preeclampsia patients during a Phase 2 trial, offering hope for improved maternal and fetal outcomes.
